WebNov 15, 2016 · The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in Her2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib WebMay 28, 2024 · The CompassHER2 trials, EA1181 and A011801, leverage pCR to tailor post neoadjuvant therapy in HER2+ EBC. EA1181 is a NAT de-escalation trial of a …
CompassHER2-pCR: Decreasing Chemotherapy for Breast …
WebA011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib WebAug 18, 2024 · Since the pivotal trial in 1976 by Bonadonna et al 1 demonstrating the benefits of adjuvant polychemotherapy in reducing breast cancer (BC) ... or can be enrolled in the phase III CompassHER2-RD trial, randomly assigning patients to adjuvant T-DM1 with or without the addition of tucatinib. If positive, these trials could further refine ... fujifilm instax sq6 instant camera film
The COMPASSHER2 Trials (COMprehensive Use of Pathologic …
WebJan 10, 2024 · This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa … WebThis trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. WebEA1181 / CompassHER2 pCR . ... All patients undergo mammogram, ultrasound, and collection of blood throughout the trial, and MRI and echocardiogram (ECHO) or … fujifilm instax sq10 hybrid camera